关于前列腺癌无进展生存的临床基因组见解
Kelvin Ofori-Minta1, Bofei Wang2, Jonathon E Mohl1,3
1Department of Mathematical Sciences, The University of Texas at El Paso, El Paso, TX 79968, USA.
International journal of environmental research and public health
|February 27, 2026
概括
这项研究整合了临床和基因组数据,以预测前列腺癌 (PrCa) 的进展. 临床基因组模型能够准确地识别高风险患者,改善PrCa.个性化治疗策略.
科学领域:
- 在瘤学瘤学.
- 基因组学就是基因组学.
- 生物信息学是一种生物信息学.
背景情况:
- 前列腺癌 (PrCa) 是男性的全球领先癌症,需要先进的预后工具.
- 目前的PrCa评估依赖于有限的临床参数,突显了综合临床基因组方法的需要.
- 早期检测和准确的风险分层对于有效的PrCa治疗和改善患者结果至关重要.
研究的目的:
- 评估临床基因组资料在预测前列腺癌患者无进展生存 (PFS) 的预后价值.
- 为了比较三个不同的生存模型在评估PrCa进展风险方面的表现.
- 确定PrCa进展的关键临床和基因组预测因素.
主要方法:
- 通过cBioPortal利用了来自癌症基因组图谱 (TCGA) 的494名PrCa患者队列.
- 雇员处罚的考克斯模型,随机生存森林和深度学习生存神经网络用于生存分析.
- 综合临床特征和单核酸变异数据用于预后建模.
主要成果:
- 生存模型在测试数据上取得了强大的歧视性表现 (哈雷尔C指数0.80-0.87).
- 始终确定了新辅助治疗史,癌症状况,瘤复发,以及MYH6基因作为PrCa PFS的显著预测因素.
- 所有模型都表现出强大的能力来根据进展风险对患者进行排名.
结论:
- 临床基因组数据整合提高了前列腺癌无进展生存率的预测.
- 这项研究强调了将基因组信息与个人化瘤学的临床数据相结合的重要性.
- 这些发现支持开发先进的模型,以改善PrCa风险分层和治疗决策.
更多相关视频
12:13Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
Published on: November 19, 2019
7.3K
13:19Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
Published on: November 2, 2013
17.2K
相关概念视频
Tumor Progression
7.6K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.6K
mTOR Signaling and Cancer Progression
4.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
4.9K
Pharmacogenomics: Identification of New Drug Targets
53
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
53
Cancer-Critical Genes I: Proto-oncogenes
11.6K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
11.6K
